Who May Qualify for Valeda Light Therapy for Dry AMD in the United States

Valeda light therapy is intended for selected patients with dry age-related macular degeneration in the United States who meet specific clinical criteria. Eligibility is typically based on the stage of AMD, retinal imaging findings, and overall eye health. The treatment is generally considered for people with intermediate dry AMD and no signs of wet disease, while certain medications, retinal conditions, or advanced damage may rule it out.

Who May Qualify for Valeda Light Therapy for Dry AMD in the United States

A retina specialist does not decide on light-based treatment from diagnosis alone. For people with dry age-related macular degeneration, candidacy is usually based on a combination of factors: how advanced the disease is, what retinal imaging shows, how well a person can see with correction, and whether other eye conditions are present. In the United States, that evaluation is typically done in a specialty eye clinic, where the goal is to match the patient to the most appropriate care plan rather than assume one option fits everyone.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Dry AMD eligibility criteria

In general, dry AMD eligibility criteria center on a confirmed diagnosis of dry, not wet, age-related macular degeneration and a retinal appearance that fits the intended use of the therapy. Doctors usually consider whether the macula still has enough functional tissue to potentially benefit, whether vision loss is linked to dry AMD rather than another cause, and whether the patient can complete a treatment schedule that may require repeated office visits. A stable medical and eye history also matters, because some coexisting problems can change whether treatment is reasonable.

Intermediate-stage macular degeneration

Many discussions about candidacy focus on intermediate-stage macular degeneration. This stage often includes larger drusen, pigment changes, or other signs that the disease has moved beyond the earliest phase but has not yet progressed to severe central damage. A person in this range may be more likely to be evaluated closely for treatment than someone with only minimal early changes. At the same time, a very advanced eye with major scarring or extensive damage may not be considered an ideal match, because the expected response can be different.

Eye exams used to assess candidacy

Eye exams used to assess candidacy usually go beyond a standard vision check. A clinician may perform a dilated retinal exam, best-corrected visual acuity testing, optical coherence tomography to look at retinal layers, and color fundus photography to document drusen and pigment changes. Some practices may also use fundus autofluorescence or other imaging tools to better understand retinal health. These tests help answer practical questions: Is the disease truly dry AMD, how active or advanced is it, and are there findings that suggest another diagnosis or a different treatment path?

Non-invasive light therapy for retinal health

Non-invasive light therapy for retinal health is typically described as an office-based approach that uses specific wavelengths of light rather than injections or surgery. For patients being considered for Valeda, an eye specialist may explain that the treatment is designed to be non-destructive and that candidacy depends on whether the retina fits the clinical profile the device is meant to address. It is not viewed as a cure for AMD, and it does not replace regular monitoring, lifestyle guidance, or other supportive measures that may still be recommended.

To understand where this option fits, it helps to compare it with other real products and services commonly discussed in dry AMD care.


Product/Service Name Provider Key Features Cost Estimation
Valeda Light Delivery System LumiThera In-office photobiomodulation for selected dry AMD patients; non-invasive and light-based Clinic pricing and insurance coverage vary
PreserVision AREDS 2 Formula Bausch + Lomb Oral AREDS2 supplement commonly used in discussions about intermediate AMD risk reduction; not a device treatment Retail cost varies by package size and seller
Eylea HD Regeneron Anti-VEGF injection generally used for wet AMD, not routine dry AMD treatment Office and insurance costs vary widely
Low Vision Rehabilitation Wilmer Eye Institute Training, tools, and support to help people use remaining vision in daily life Program fees and coverage vary

Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.


Real-world costs can differ substantially. An over-the-counter supplement may have a fairly predictable retail price, while office-based treatments and rehabilitation services can vary by region, provider, insurance plan, and visit frequency. Even when a clinic offers a service, out-of-pocket expenses may depend on medical necessity reviews, billing codes, and whether the patient has secondary coverage. That is why cost discussions are usually most useful after the eye exam confirms whether a person is even an appropriate candidate.

Signs a patient may not qualify

Signs a patient may not qualify often become clear during the exam workup. Examples can include evidence of wet AMD, major central scarring, another retinal disease that better explains the vision loss, or media opacity that prevents the specialist from properly evaluating the macula. A doctor may also delay or avoid treatment if the expected benefit is uncertain under current labeling or if the patient cannot tolerate the testing and follow-up needed to track response. Not qualifying does not mean there are no options; it usually means another management strategy is more suitable.

In practice, candidacy is less about a single symptom and more about the full clinical picture. People most likely to be considered are those with confirmed dry AMD, findings consistent with the appropriate stage of disease, and eye exam results that support the use of a non-invasive light-based approach. Because dry AMD can look different from one patient to another, the deciding factor is usually a retina specialist’s assessment of disease stage, retinal structure, visual function, and any competing eye conditions.